About the Company
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALXN News
Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life ...
Alexion Spikes Amid Report Activist Elliott Management Is Pushing for Change
Alexion Pharmaceuticals Inc. (ALXN) shares surged almost 6% on Friday, Dec. 8, amid reports that activist investor Elliott Management is pressing for major changes on the company's board if it ...
PAC Profile: Alexion Pharmaceuticals
*Based on data released by the Federal Election Commission on April 20, 2024 except for independent expenditure and communication cost, contributions to federal candidates, and contributions from ...
Alexion Pharmaceuticals spotlights rare disease NMOSD in short film
Alexion Pharmaceuticals, AstraZeneca’s rare disease unit, shined a light on neuromyelitis optica spectrum disorder (NMOSD), a severe neurological disease, in a short film that debuted Thursday. While ...
Search Results for "alexion":
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there ...
‘New beginning’: Weymouth man who received first genetically edited pig kidney transplant discharged
Slayman also received an infusion of novel immunosuppressant drugs, tegoprubart, provided by Eledon Pharmaceuticals Inc., and ravulizumab, provided by Alexion Pharmaceuticals Inc. The procedure ...
Alexion data at AAN 2024 demonstrate how Ultomiris & Soliris can transform outcomes for rare neurological diseases
Alexion data at AAN 2024 demonstrate how Ultomiris & Soliris can transform outcomes for rare neurological diseases: Cambridge, UK Tuesday, April 9, 2024, 11:00 Hrs [IST] Alexion, ...
Alexion Pharmaceuticals patents complement C1s subcomponent inhibitors
An Alexion Pharmaceuticals Inc. patent describes new complement C1s subcomponent (C1S) inhibitors potentially useful for the treatment of immune thrombocytopenia purpura, lupus nephritis, amyotrophic ...
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
We are delighted to welcome Tony to our Board of Directors as we build on our leadership in delivering therapeutics to the suprachoroidal space,” said Clay Thorp, Chair of the Clearside Board of ...
CORRECTING and REPLACING PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical
The updated release reads: PHARMAESSENTIA APPOINTS ROBERT GELLER, M.D. AS HEAD OF MEDICAL. PharmaEssentia USA Corporation, a ...
Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc. was founded in 1992 and operates in New Haven, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC ...
Loading the latest forecasts...